Assetmark Inc. Purchases 3,734 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Assetmark Inc. boosted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 9.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 42,759 shares of the biotechnology company’s stock after purchasing an additional 3,734 shares during the period. Assetmark Inc.’s holdings in Sarepta Therapeutics were worth $5,199,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in SRPT. Wellington Management Group LLP lifted its stake in Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares during the last quarter. Erste Asset Management GmbH purchased a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $79,425,000. Janus Henderson Group PLC increased its position in shares of Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after acquiring an additional 543,143 shares during the period. Soros Fund Management LLC purchased a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $25,800,000. Finally, Swedbank AB purchased a new position in shares of Sarepta Therapeutics during the fourth quarter worth approximately $16,706,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Down 2.4 %

NASDAQ SRPT opened at $103.03 on Friday. The company has a market capitalization of $10.00 billion, a PE ratio of 82.42 and a beta of 0.79. The company has a fifty day moving average of $114.11 and a 200 day moving average of $121.43. Sarepta Therapeutics, Inc. has a 1 year low of $99.50 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on SRPT shares. HC Wainwright reaffirmed a “sell” rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Piper Sandler reduced their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Royal Bank of Canada reduced their target price on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Scotiabank began coverage on shares of Sarepta Therapeutics in a research report on Friday. They set a “sector perform” rating and a $105.00 target price on the stock. Finally, StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $170.41.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.